FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Titel:
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Auteur:
Heinemann, Volker von Weikersthal, Ludwig Fischer Decker, Thomas Kiani, Alexander Vehling-Kaiser, Ursula Al-Batran, Salah-Eddin Heintges, Tobias Lerchenmüller, Christian Kahl, Christoph Seipelt, Gernot Kullmann, Frank Stauch, Martina Scheithauer, Werner Hielscher, Jörg Scholz, Michael Müller, Sebastian Link, Hartmut Niederle, Norbert Rost, Andreas Höffkes, Heinz-Gert Moehler, Markus Lindig, Reinhard U Modest, Dominik P Rossius, Lisa Kirchner, Thomas Jung, Andreas Stintzing, Sebastian